Toronto, Ontario–(Newsfile Corp. – March 23, 2021) – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF)(“Mindset” or the “Company“), a biotechnology company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce that it has entered a co-development agreement with InterVivo Solutions Inc. (“InterVivo” or “IVS“), to co-develop a new…


Previous articleMydecine Innovations Group Announces Migration to NEO Exchange
Next articleNuminus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies